Safety Study of the Novel Drug Dimebon to Treat Patients With Huntington's Disease

Medivation, Inc.9 enrolled

Overview

This study is being conducted to determine the safety and tolerability of Dimebon in people with Huntington's disease after short-term exposure (one week) and after longer exposure (three months). Also, the study will assess whether or not there is an effect of Dimebon on the symptoms of Huntington's disease, including cognitive (thinking abilities), motor (movement), behavior, and overall functioning.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Huntington's Disease

Interventions

DimebonDRUG

Dimebon 10 or 20 mg TID x 7 days

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Clinical features of Huntington's disease and a confirmatory family history of HD, or a CAG repeat expansion greater than or equal to 36 * Stage I,II,III HD and a total functional capacity greater than or equal to 5 on the Unified Huntington's Disease Rating Scale Exclusion Criteria: * Clinical evidence of unstable medical illness

Locations (1)

Huntington Study Group

Rochester, New York, United States

Outcomes

Primary Outcomes

Dose-limiting toxicities

Time frame: 7 days

Secondary Outcomes

Unified Huntington's Disease Rating Scale

Time frame: 7 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.